Under the terms of the non-exclusive agreement, Boehringer Ingelheim will have access to VTU Technology’s ready-to-use high expression Pichia system in close collaboration with the VTU team for the development and manufacture of therapeutic proteins.
Professor Dr Rolf G. Werner, senior vice president of Boehringer Ingelheim’s Biopharmaceuticals Division said, With a reputation for outstanding innovation, VTU Technology is well positioned to play an important role as a partner in our collaboration. This collaboration will bring a proven high-expression Pichia technology offering us great value and further flexibility in our contract manufacturing business, while complementing our existing scaffold technology platforms. We believe this collaboration will benefit both our partners and our customers. We look forward to working with the VTU Technology team.